Literature DB >> 23217253

Is hyperinsulinemia required to develop overeating-induced obesity?

Christoph Buettner1.   

Abstract

Type 2 diabetes is characterized by insulin resistance, and the hyperinsulinemia commonly observed in patients is thought to be a compensatory response. Yet it has been difficult to disentangle cause and effect. Mehran et al. (2012) provide genetic evidence that a reduction of insulin secretion prevents high-fat feeding-induced obesity.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 23217253      PMCID： PMC3740751          DOI： 10.1016/j.cmet.2012.11.009

Source DB:  PubMed          Journal:  Cell Metab        ISSN： 1550-4131            Impact factor:   27.287


  6 in total

1.  Brain insulin controls adipose tissue lipolysis and lipogenesis.

Authors:  Thomas Scherer; James O'Hare; Kelly Diggs-Andrews; Martina Schweiger; Bob Cheng; Claudia Lindtner; Elizabeth Zielinski; Prashant Vempati; Kai Su; Shveta Dighe; Thomas Milsom; Michelle Puchowicz; Ludger Scheja; Rudolf Zechner; Simon J Fisher; Stephen F Previs; Christoph Buettner
Journal:  Cell Metab       Date:  2011-02-02       Impact factor: 27.287

Review 2.  Central insulin action in energy and glucose homeostasis.

Authors:  Leona Plum; Bengt F Belgardt; Jens C Brüning
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

3.  A novel high-affinity peptide antagonist to the insulin receptor.

Authors:  Lauge Schäffer; Christian L Brand; Bo F Hansen; Ulla Ribel; Allan C Shaw; Rita Slaaby; Jeppe Sturis
Journal:  Biochem Biophys Res Commun       Date:  2008-09-07       Impact factor: 3.575

4.  Hyperinsulinemia drives diet-induced obesity independently of brain insulin production.

Authors:  Arya E Mehran; Nicole M Templeman; G Stefano Brigidi; Gareth E Lim; Kwan-Yi Chu; Xiaoke Hu; Jose Diego Botezelli; Ali Asadi; Bradford G Hoffman; Timothy J Kieffer; Shernaz X Bamji; Susanne M Clee; James D Johnson
Journal:  Cell Metab       Date:  2012-12-05       Impact factor: 27.287

Review 5.  Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?

Authors:  Michael H Shanik; Yuping Xu; Jan Skrha; Rachel Dankner; Yehiel Zick; Jesse Roth
Journal:  Diabetes Care       Date:  2008-02       Impact factor: 19.112

6.  Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling.

Authors:  Aleksey V Matveyenko; David Liuwantara; Tatyana Gurlo; David Kirakossian; Chiara Dalla Man; Claudio Cobelli; Morris F White; Kyle D Copps; Elena Volpi; Satoshi Fujita; Peter C Butler
Journal:  Diabetes       Date:  2012-06-11       Impact factor: 9.461
  6 in total
  4 in total

Review 1.  Molecular pathways linking adipose innervation to insulin action in obesity and diabetes mellitus.

Authors:  Adilson Guilherme; Felipe Henriques; Alexander H Bedard; Michael P Czech
Journal:  Nat Rev Endocrinol       Date:  2019-04       Impact factor: 43.330

2.  CNC-bZIP protein Nrf1-dependent regulation of glucose-stimulated insulin secretion.

Authors:  Hongzhi Zheng; Jingqi Fu; Peng Xue; Rui Zhao; Jian Dong; Dianxin Liu; Masayuki Yamamoto; Qingchun Tong; Weiping Teng; Weidong Qu; Qiang Zhang; Melvin E Andersen; Jingbo Pi
Journal:  Antioxid Redox Signal       Date:  2015-02-18       Impact factor: 8.401

3.  Rutaecarpine ameliorates hyperlipidemia and hyperglycemia in fat-fed, streptozotocin-treated rats via regulating the IRS-1/PI3K/Akt and AMPK/ACC2 signaling pathways.

Authors:  Xu-qiang Nie; Huai-hong Chen; Jian-yong Zhang; Yu-jing Zhang; Jian-wen Yang; Hui-jun Pan; Wen-xia Song; Ferid Murad; Yu-qi He; Ka Bian
Journal:  Acta Pharmacol Sin       Date:  2016-03-14       Impact factor: 6.150

4.  Carbohydrate modified diet & insulin sensitizers reduce body weight & modulate metabolic syndrome measures in EMPOWIR (enhance the metabolic profile of women with insulin resistance): a randomized trial of normoglycemic women with midlife weight gain.

Authors:  Harriette R Mogul; Ruth Freeman; Khoa Nguyen; Michael Frey; Lee-Ann Klein; Sheila Jozak; Karen Tanenbaum
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.